Mode
Text Size
Log in / Sign up

Single-port robotic-assisted radical prostatectomy provides comparable oncological outcomes to multi-port techniques with improved recoverySingle port surgery offers faster recovery for prostate cancer patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that SP-RARP offers improved recovery and cosmetic outcomes compared to MP-RARP with equivalent oncological safety.

This umbrella review synthesizes meta-analyses comparing single-port robotic-assisted radical prostatectomy (SP-RARP) to multi-port RARP for patients with prostate cancer. The authors conclude that SP-RARP is a safe and feasible alternative to the standard multi-port approach.

Key findings indicate that SP-RARP results in significantly shorter hospital stays, smaller incision lengths, reduced postoperative pain, and lower opioid requirements compared to MP-RARP. Additionally, SP-RARP showed greater feasibility for ambulatory or same-day discharge. Conversely, operative time, console time, estimated blood loss, and overall complication rates were generally comparable between the two techniques.

Regarding clinical outcomes, no significant differences were found between SP-RARP and MP-RARP regarding functional outcomes (urinary continence and potency recovery) or oncological outcomes (positive surgical margin rates and biochemical recurrence). The authors note that the evidence is limited by methodological weaknesses in the included meta-analyses and the fact that primary studies were predominantly retrospective. Clinical application should account for these limitations when choosing a surgical approach.

How this fits prior evidence

This umbrella review addresses gaps regarding the comparative efficacy of surgical techniques in prostate cancer management. While prior coverage has focused on diagnostic tools such as mpMRI, AI detection, and biopsy methods, this finding provides evidence on surgical alternatives. It confirms that SP-RARP is a viable alternative to MP-RARP without compromising oncological or functional results.

When facing a diagnosis of prostate cancer, the surgical path is a major decision. Patients often weigh the effectiveness of the operation against how quickly they can return to normal life. New evidence suggests that using a single-port robotic approach—where tools enter through one small incision—can improve the immediate recovery experience.

This review compared the single-port method to the traditional multi-port robotic surgery. The findings show that patients who had the single-port procedure experienced shorter hospital stays, smaller incisions, and less pain after surgery. They also required fewer opioids and were more likely to be eligible for same-day discharge. These improvements make the recovery process smoother and more comfortable.

Importantly, these benefits do not come at a cost to the primary goals of the surgery. The study found that both methods performed equally well in terms of cancer control, urinary function, and potency recovery. While the data comes from some older reports and has some limitations, it suggests that single-port surgery is a safe and practical choice for patients seeking better cosmetic results and faster healing.

What this means for you:
Single-port robotic surgery offers faster recovery and less pain without affecting cancer outcomes or function.

Common questions

Does single-port surgery help with recovery?

Yes, patients who underwent single-port robotic surgery had significantly shorter hospital stays and smaller incisions compared to those who had multi-port surgery. They also reported less pain after the procedure and required fewer opioids.

Is it as effective for cancer treatment?

The results show that both single-port and multi-port surgeries are equivalent when it comes to cancer outcomes, such as positive surgical margin rates and biochemical recurrence. Both methods are equally effective at treating the cancer.

Will my physical functions be affected?

There were no significant differences between the two types of surgery regarding functional outcomes. Both methods showed similar results for urinary continence and potency recovery after the procedure.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Single-port robotic-assisted radical prostatectomy (SP-RARP) has emerged as a minimally invasive alternative to conventional multi-port RARP (MP-RARP), aiming to reduce surgical access morbidity while maintaining oncological and functional outcomes. We performed an umbrella review to synthesize and critically appraise the available meta-analytic evidence comparing SP-RARP and MP-RARP. A systematic search of MEDLINE, EMBASE, and CENTRAL was conducted from inception to December 2025. Meta-analyses comparing SP-RARP with MP-RARP in adults undergoing radical prostatectomy for prostate cancer were included. Two reviewers independently screened studies, extracted data, and assessed methodological quality using AMSTAR-2. Outcomes evaluated included perioperative, functional, oncological, cosmetic, and economic parameters. Due to overlap of primary studies and methodological heterogeneity, findings were synthesized descriptively. Eight meta-analyses were included. Across pooled evidence, SP-RARP demonstrated significantly shorter hospital stay, smaller incision length, reduced postoperative pain, lower opioid requirements, and greater feasibility for ambulatory or same-day discharge pathways. Operative time, console time, estimated blood loss, and overall complication rates were generally comparable between approaches. Functional outcomes, including urinary continence and potency recovery, showed no significant differences. Similarly, oncological outcomes such as positive surgical margin rates and biochemical recurrence were equivalent. Current evidence suggests that SP-RARP is a safe and feasible alternative to MP-RARP, offering improved recovery and cosmetic outcomes without compromising oncological or functional results. However, the certainty of evidence remains limited by methodological weaknesses and predominantly retrospective data. High-quality prospective multicenter studies with long-term follow-up are needed to define the role of SP-RARP in contemporary prostate cancer surgery.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.